Strategies to address reimbursement restrictions for Hep C treatment: Lessons from Australia

Event Date: 
6 February 2017, 15:00 EST

Monday February 6th 3-4:30pm EST
Presented by: CATIE, CanHep C and The Kirby Institute

In Canada, direct-acting antiviral (DAA) hepatitis C treatments are costly, so provinces and territories limit access to patients based on fibrosis stage and other criteria such as HIV coinfection.  How can we move beyond this approach and achieve a model of access for all?

This webinar, taking place February 6th, 3:00 p.m. ET, by CATIE, CanHepC, CTAC and The Kirby Institute, will explore how Canada could move beyond its current restrictive and inconsistent approach to DAA access.  The webinar will showcase the Australian model, which allows all people access to hepatitis C treatment, including people who inject drugs and people in prison.  This webinar will examine what social and environmental factors led to this model and what policy-makers, service providers and community activists in Canada can learn from the Australian experience.

Learn from experts such as Alison Marshall and Greg Dore of Australia’s The Kirby Institute; and Helen Tyrell of Hepatitis Australia. Engage in discussion with Adam Cook of CTAC and Action Hepatitis Canada; Community Organizer Zoe Dodd.

Powerpoint/PDF File: